Skip to main content

Table 4 Drug compliance and adverse events

From: New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study

  Total (n = 109)
Drug compliance
 First 4 weeks compliance (%) 84.4 ± 21.2
 Second 4 weeks compliance (%) 91.6 ± 14.9
 Whole period compliance (%) 84.7 ± 21.2
Adverse events
 Dyspepsia (%) 10 (47.6)
 Diarrhea (%) 3 (14.3)
 Constipation (%) 3 (14.3)
 Vomiting (%) 2 (9.5)
 Skin rash (%) 2 (9.5)
 Leg cramps (%) 1 (4.8)
 Total adverse effects (n) 21
  1. Data are presented as mean ± standard deviation or number (percentage) of subjects
\